Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Arvinas | History Defined

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m

Arvinas Q1 Earnings Call Highlights

Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation. President and Chief Executive Officer Randy Teel said the app

7 Analysts Have This to Say About Arvinas

7 Analysts Have This to Say About Arvinas

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analyst Ratings for Arvinas

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022

Arvinas: Q1 Earnings Insights

Arvinas (NASDAQ:ARVN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

What 6 Analyst Ratings Have To Say About Arvinas

Over the past 3 months, 6 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

Expert Ratings For Arvinas

Expert Ratings For Arvinas

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

Arvinas Earnings Perspective: Return On Capital Employed

Arvinas Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Arvinas (NASDAQ:ARVN) reported Q4 sales of $26.30 million. Earnings fell to a loss of $53.00 million, resulting in a 13.35% decrease from last quarter.

Where Arvinas Stands With Analysts

Where Arvinas Stands With Analysts

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

B of A Securities

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

415,593 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play